<DOC>
	<DOCNO>NCT00755027</DOCNO>
	<brief_summary>The purpose study determine whether rasagiline effective treatment apathy patient Parkinson 's disease .</brief_summary>
	<brief_title>Rasagiline Apathy Parkinson 's Disease</brief_title>
	<detailed_description>The primary objective study evaluate efficacy rasagiline patient Parkinson 's disease ( PD ) apathy . Secondary objective 1 ) evaluate affective cognitive response rasagiline correlate apathy 2 ) investigate metabolic neurophysiologic correlate behavioural , cognitive emotional , aspects apathy PD . This exploratory , randomize , double-blind , placebo control , parallel-group study . 40 PD patient apathy without dementia recruit . Rasagiline 1 mg match placebo administer daily conjunction subject ' usual oral antiparkinsonian medication 12 week . Patients evaluate screen ( -7 day ) baseline ( 0 ) , well week 4 , 8 , 12 . A perfusion SPECT perform baseline week 12 . The study conduct Movement Disorders Unit Neurology Department Sant Pau Hospital ( Barcelona , Spain ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Patients idiopathic PD optimally treat motor deficit stable dos LDopa and/or dopamine agonist show nonzero score item 4 ( motivation/initiative ) Unified Parkinson 's Disease Rating Scale ( UPDRS ) Dementia associate PD accord DSM IV criterion . History primary psychiatric illness Axis I diagnose accord Structured Clinical Interview DSMIV Patients complain acute mood cognitive fluctuation response dopaminergic medication Patients treat MAO inhibitor ( include Selegiline ) , fluoxetine fluvoxamine previous month inclusion . Also exclude patient neurological disorder PD , unstable systemic disease pregnant possibly pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Rasagiline</keyword>
</DOC>